Riva Fineman

765 total citations
30 papers, 501 citations indexed

About

Riva Fineman is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Riva Fineman has authored 30 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 9 papers in Hematology. Recurrent topics in Riva Fineman's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Riva Fineman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Riva Fineman collaborates with scholars based in Israel and United States. Riva Fineman's co-authors include Tsila Zuckerman, Noam Benyamini, Jacob M. Rowe, Tamar Tadmor, H. Sprecher, I. Oren, Aaron Polliack, Osnat Bairey, Lev Shvidel and Neta Goldschmidt and has published in prestigious journals such as Blood, The American Journal of Cardiology and British Journal of Haematology.

In The Last Decade

Riva Fineman

30 papers receiving 494 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Riva Fineman Israel 11 171 165 151 125 124 30 501
Ola Blennow Sweden 13 79 0.5× 268 1.6× 194 1.3× 84 0.7× 30 0.2× 26 628
Jadwiga Dwilewicz‐Trojaczek Poland 12 500 2.9× 139 0.8× 174 1.2× 386 3.1× 48 0.4× 47 841
V. Rodríguez United States 11 25 0.1× 162 1.0× 83 0.5× 55 0.4× 48 0.4× 32 468
Anne Thiebaut‐Bertrand France 16 82 0.5× 241 1.5× 326 2.2× 130 1.0× 8 0.1× 29 717
F. Menichetti Italy 9 49 0.3× 217 1.3× 128 0.8× 45 0.4× 24 0.2× 14 410
Maria Licciardello Italy 11 27 0.2× 125 0.8× 86 0.6× 18 0.1× 57 0.5× 20 367
Maurizio Buelli Italy 7 53 0.3× 440 2.7× 67 0.4× 19 0.2× 41 0.3× 13 599
Sonoko Shimoji Japan 9 30 0.2× 84 0.5× 65 0.4× 36 0.3× 17 0.1× 24 449
Yu Akahoshi Japan 13 53 0.3× 183 1.1× 35 0.2× 11 0.1× 19 0.2× 64 521
Clara Minotti Italy 13 24 0.1× 160 1.0× 104 0.7× 9 0.1× 83 0.7× 35 490

Countries citing papers authored by Riva Fineman

Since Specialization
Citations

This map shows the geographic impact of Riva Fineman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riva Fineman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riva Fineman more than expected).

Fields of papers citing papers by Riva Fineman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Riva Fineman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riva Fineman. The network helps show where Riva Fineman may publish in the future.

Co-authorship network of co-authors of Riva Fineman

This figure shows the co-authorship network connecting the top 25 collaborators of Riva Fineman. A scholar is included among the top collaborators of Riva Fineman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Riva Fineman. Riva Fineman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rozenberg, Ayal, Shahar Shelly, Riva Fineman, et al.. (2025). CCR5 predicts neurotoxicity in CAR‐T‐cell therapy. British Journal of Haematology. 207(3). 1133–1137. 1 indexed citations
2.
Gurion, Ronit, Uri Rozovski, Gilad Itchaki, et al.. (2021). Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 107(3). 715–720. 44 indexed citations
3.
Benjamini, Ohad, Lior Rokach, Gilad Itchaki, et al.. (2021). Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica. 107(3). 625–634. 73 indexed citations
4.
Beyar‐Katz, Ofrat, Noa Lavi, Israel Henig, et al.. (2019). Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. Leukemia & lymphoma. 60(10). 2449–2456. 10 indexed citations
5.
Tadmor, Tamar, Ilana Levy, Yair Herishanu, et al.. (2019). Primary peg-filgrastim prophylaxis versus filgrastim given “on demand” for neutropenia during therapy with cladribine for hairy cell leukemia. Leukemia Research. 82. 24–28. 2 indexed citations
6.
Joffe, Erel, Neta Goldschmidt, Osnat Bairey, et al.. (2018). Outcomes of second‐line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. European Journal Of Haematology. 101(3). 399–406. 5 indexed citations
7.
Herishanu, Yair, Neta Goldschmidt, Osnat Bairey, et al.. (2018). Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel. Anticancer Research. 38(11). 6423–6429. 8 indexed citations
8.
Joffe, Erel, Osnat Bairey, Riva Fineman, et al.. (2017). Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival. Hematological Oncology. 36(1). 128–135. 3 indexed citations
9.
Beyar‐Katz, Ofrat, Tsila Zuckerman, Riva Fineman, et al.. (2015). Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy. Biology of Blood and Marrow Transplantation. 22(6). 975–981. 23 indexed citations
10.
11.
Fineman, Riva, et al.. (2014). Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting. Rambam Maimonides Medical Journal. 5(4). e0027–e0027. 2 indexed citations
12.
Tadmor, Tamar, Lev Shvidel, Neta Goldschmidt, et al.. (2014). Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group.. PubMed. 34(2). 785–90. 32 indexed citations
13.
Oren, Ilana, Hannah Sprecher, Renato Finkelstein, et al.. (2013). Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial. American Journal of Infection Control. 41(12). 1167–1172. 69 indexed citations
14.
Zuckerman, Tsila, Tamar Katz, Riva Fineman, et al.. (2012). Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: Risk stratified approach with a long‐term follow‐up. American Journal of Hematology. 87(9). 875–879. 5 indexed citations
15.
Bonstein, Lilach, et al.. (2012). Alloimmune platelet transfusion refractoriness circumvented by allogeneic stem cell transplantation. Transfusion. 53(5). 1019–1023. 2 indexed citations
16.
Zuckerman, Tsila, Noam Benyamini, H. Sprecher, et al.. (2010). SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplantation. 46(9). 1226–1230. 63 indexed citations
17.
18.
Landau, Dan‐Avi, et al.. (2006). Long-term survivors of childhood malignancies--aeromedical dilemmas and implications.. PubMed. 77(12). 1266–70. 2 indexed citations
19.
20.
Harpaz, David, et al.. (1996). Effects of high gravity on cardiac dimensions in trained air crew. The American Journal of Cardiology. 77(14). 1258–1260. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ola Blennow Breakdown of academic impact, for papers by Jadwiga Dwilewicz‐Trojaczek Breakdown of academic impact, for papers by V. Rodríguez Breakdown of academic impact, for papers by Anne Thiebaut‐Bertrand Breakdown of academic impact, for papers by F. Menichetti Breakdown of academic impact, for papers by Maria Licciardello Breakdown of academic impact, for papers by Maurizio Buelli Breakdown of academic impact, for papers by Sonoko Shimoji Breakdown of academic impact, for papers by Yu Akahoshi Breakdown of academic impact, for papers by Clara Minotti
Rankless by CCL
2026